Recombinant Zoster Vaccine Effective After Autologous Stem Cell Transplant

Incidence of herpes zoster infection was significantly reduced with adjuvanted recombinant zoster vaccine versus placebo in a high-risk immunosuppressed group.

The recombinant zoster vaccine, approved in the U.S. in 2017, contains a novel adjuvant and was previously shown to be highly effective (>90%) in immunocompetent persons 50 years of age and older (NEJM Infect Dis Jan 2018). A good immune response to the vaccine was also seen in a prior phase I/IIa study involving immunosuppressed autologous hematopoietic stem cell transplant (HSCT) recipients at increased risk for herpes zoster infection (Blood 2014; 124:2921).

Now, investigators have conducted an industry-funded, international, randomized, phase III study to examine the clinical efficacy of the recombinant vaccine versus placebo in 1846 immunosuppressed, autologous HSCT recipients. Approximately 53% had multiple myeloma, 42% had lymphoma, a…

Reviewing Author

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Recombinant Zoster Vaccine Effective After Autologous Stem Cell Transplant

Topics

Reviewing Author